93 related articles for article (PubMed ID: 10868311)
21. Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C.
Ito N; Kawata S; Tamura S; Kiso S; Tsushima H; Maeda Y; Yamasaki E; Igura T; Matsuzawa Y
Hepatology; 1996 Apr; 23(4):669-75. PubMed ID: 8666316
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver.
Yamagata Y; Yuasa Y; Yamamoto K; Okamoto K; Igari Y; Iga K; Ogawa Y
J Interferon Cytokine Res; 2000 Feb; 20(2):153-60. PubMed ID: 10714550
[TBL] [Abstract][Full Text] [Related]
24. 2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
Merritt JA; Meltzer DM; Ball LA; Borden EC
Prog Clin Biol Res; 1985; 202():423-30. PubMed ID: 3832076
[TBL] [Abstract][Full Text] [Related]
25. 2',5'-Oligoadenylate synthetase and interferon in peripheral blood after rubella, measles, or mumps live virus vaccine.
Tilles JG; Balkwill F; Davilla J
Proc Soc Exp Biol Med; 1987 Oct; 186(1):70-4. PubMed ID: 3628253
[TBL] [Abstract][Full Text] [Related]
26. [Interferon status and the activity of dsRNA-dependent enzymes in volunteers and influenza patients receiving human recombinant alpha 2-interferon (reaferon)].
Lavrukhina LA; Sokolova TM; Suetina IA; Kniazeva LD; Mironova LL
Vopr Virusol; 1988; 33(5):580-5. PubMed ID: 2464241
[TBL] [Abstract][Full Text] [Related]
27. Induction of blood 2',5'-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau.
Nakajima A; Sokawa Y
J Interferon Cytokine Res; 2002 Mar; 22(3):397-402. PubMed ID: 12034048
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of 2,5-oligoadenylate synthetase and protein kinase activities in clinical studies of larifan and recombinant interferon alpha in volunteers].
Sokolova TM; Nosik NN; Lopatina OA; Krylov VF
Antibiot Khimioter; 1991 Jul; 36(7):42-5. PubMed ID: 1953190
[TBL] [Abstract][Full Text] [Related]
29. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
30. Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in humans.
Witter FR; Woods AS; Griffin MD; Smith CR; Nadler P; Lietman PS
Clin Pharmacol Ther; 1988 Aug; 44(2):239-43. PubMed ID: 2456175
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
Witt PL; Storer BE; Bryan GT; Brown RR; Flashner M; Larocca AT; Colby CB; Borden EC
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):191-200. PubMed ID: 8471593
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Musolino C; Grosso P; Alonci A; Allegra A; Orlando A; Cincotta M; Buda G; Squadrito G
Am J Hematol; 1993 May; 43(1):1-4. PubMed ID: 8317456
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Bain VG; Kaita KD; Yoshida EM; Swain MG; Heathcote EJ; Neumann AU; Fiscella M; Yu R; Osborn BL; Cronin PW; Freimuth WW; McHutchison JG; Subramanian GM
J Hepatol; 2006 Apr; 44(4):671-8. PubMed ID: 16487617
[TBL] [Abstract][Full Text] [Related]
34. A comparison of interferon levels with leukocyte (2'-5') oligoadenylate synthetase activity as markers of viral encephalopathies.
Kennedy CR; Tilles JG
J Interferon Res; 1988 Oct; 8(5):609-15. PubMed ID: 2466911
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of the determination of an interferon-induced enzyme activity: studies of the 2'5' oligoadenylate synthetase activity in peripheral blood lymphocytes of patients.
Chousterman S; Chousterman M; Reinert P; Thang MN
Biomed Pharmacother; 1983; 37(4):176-80. PubMed ID: 6198003
[TBL] [Abstract][Full Text] [Related]
38. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
[TBL] [Abstract][Full Text] [Related]
39. Induction of intracellular and plasma 2',5'-oligoadenylate synthetase by pentostatin.
Ho AD; Klotzbücher A; Gross A; Dietz G; Mestan J; Jakobsen H; Hunstein W
Leukemia; 1992 Mar; 6(3):209-14. PubMed ID: 1564958
[TBL] [Abstract][Full Text] [Related]
40. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
